Preserving the future of medicine: standardizing leukapheresis materials with cryopreservation for scalable cell therapies
Sponsor
With the rapid advancement of cell therapy, ensuring reliable and consistent cellular starting material is critical for therapeutic manufacturing. A growing challenge in this space is managing variability in leukapheresis starting materials, which impacts the scalability and manufacturability of life-saving cell therapies. Standardizing processes across multiple collection, processing, and manufacturing sites is vital to maintain consistent quality across different regions. For companies navigating complex processes for cryopreservation, challenges such as site qualification, material transport, and resource allocation will arise.
This webinar panel will bring together experts to discuss these industry challenges, focusing on the differences between fresh and cryopreserved starting materials, and how to efficiently scale cell therapies from clinical to commercial phases using an optimized, end-to-end supply chain. Insights on the latest advancements in cryopreservation and strategies to address common challenges associated with leukapheresis starting materials will be shared. The discussion will also highlight the criticality of an integrated supply chain approach to support the scaling of cell therapy programs.
Attend this webinar to:
- Gain a deep understanding of how variability in leukapheresis starting material affects cell therapy product manufacturability and scalability
- Discover recent advancements in cryopreservation processes that minimize variability and improve standardization across collection and manufacturing sites
- Learn how to navigate the time, resource, and process complexities of qualifying multiple sites, with insights from a panel of industry experts
- Understand how streamlined, end-to-end logistics solutions enable seamless transportation of cryopreserved materials, ensuring the successful scale-up of cell therapy programs
SPEAKERS
You might also like
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Optimizing for the future: streamlining the production of T cell-based immunotherapies
Expediting development and manufacture of advanced therapies: critical starting materials case study
